Bibliografia UJ CM

1/11
Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Simkovic, Jiri Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A. Yimer, Tommi Salmi, Meng Ji, Jessica Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak.
Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma : interim analysis of a randomized phase III trial.
Journal of Clinical Oncology
2023 : Vol. 41, nr 5, s. 1035-1045, il., bibliogr. 22 poz.
Autor korespondencyjny: Peter Hillmen
Online First 2022-11-17
Open Access Creative Commons Attribution License CC-BY-NC-ND 4.0.
p-ISSN: 0732-183X
e-ISSN: 1527-7755
AZ
ORG
AIF
IF: 45.300
Adres url:
Streszczenie w PubMed:
2/11
Jennifer R. Brown, John C. Byrd, Paolo Ghia, Jeff P. Sharman, Peter Hillmen, Deborah M. Stephens, Clare Sun, Wojciech Jurczak, John M. Pagel, Alessandra Ferrajoli, Priti Patel, Lin Tao, Nataliya Kuptsova-Clarkson, Javid Moslehi, Richard R. Furman.
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy : pooled analysis of 762 patients
Haematologica
2022 : Vol. 107, nr 6, s. 1335-1346, il., bibliogr. 52 poz., abstr.
Autor korespondencyjny: Jennifer R. Brown
Open Access Creative Commons Attribution License CC-BY-NC 4.0
p-ISSN: 0390-6078
AZ
ORG
AIF
IF: 10.100
Adres url:
Streszczenie w PubMed:
3/11
Constantine S. Tam, Jennifer R. Brown, Brad S. Kah, Paolo Ghia, Giannopoulo Giannopoulos, Wojciech Jurczak, Martin imkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepluch, Richard Greil, Monica Tani, Marek Trneny, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Alessandra Tedeschi, Jianyong Li, Tian Tian, Lei Zhou, Carol Marimpietri, Jason C. Paik, Aileen Cohe, Jane Huang, Tadeusz Robak, Peter Hillmen.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA) : a randomised, controlled, phase 3 trial.
Lancet. Oncology
2022 : Vol. 23, nr 8, s. 1031-1043, il., bibliogr. 31 poz., sum.
Autor korespondencyjny: Tadeusz Robak, Peter Hillmen.
p-ISSN: 1470-2045
e-ISSN: 1474-5488
AZ
ORG
AIF
IF: 51.100
Adres url:
Streszczenie w PubMed:
4/11
John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O'Brien, Mustafa Nuri Yenerel, Arpad Illés, Neil Kay, Jose A. Garcia-Marco, Anthony Mato, Javier Pinilla-Ibarz, John F. Seymour, Stephane Lepretre, Stephan Stilgenbauer, Tadeusz Robak, Wayne Rothbaum, Raquel Izumi, Ahmed Hamdy, Priti Patel, Kara Higgins, Sophia Sohoni, Wojciech Jurczak.
Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia : results of the first randomized phase III trial.
Journal of Clinical Oncology
2021 : Vol. 39, nr 31, s. 3441-3452, il., bibliogr. 37 poz.
Autor korespondencyjny: John C. Byrd.
Open Access Creative Commons Attribution License CC-BY-NC ND 4.0.
p-ISSN: 0732-183X
e-ISSN: 1527-7755
AZ
ORG
AIF
IF: 50.739
Adres url:
Streszczenie w PubMed:
5/11
Richard R. Furman, John C. Byrd, Roger G. Owen, Susan M. O'Brien, Jennifer R. Brown, Peter Hillmen, Deborah M. Stephens, Nataliya Chernyukhin, Tamara Lezhava, Ahmed M. Hamdy, Raquel Izumi, Priti Patel, Marshall Baek, Beth Christian, Martin J. S. Dyer, Matthew J. Streetly, Clare Sun, Simon Rule, Michael Wang, Paolo Ghia, Wojciech Jurczak, John M. Pagel, Jeff P. Sharman.
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.
Leukemia
2021 : Vol. 35, nr 11, s. 3201-3211, il., bibliogr. 41 poz., abstr.
Autor korespondencyjny: Richard R. Furman.
p-ISSN: 0887-6924
e-ISSN: 1476-5551
AZ
ORG
AIF
IF: 12.897
Adres url:
Streszczenie w PubMed:
6/11
Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Peter Hillmen, John F. Seymour, Steven Coutre, Wojciech Jurczak, Stephen P. Mulligan, Anna Schuh, Sarit Assouline, Clemens-Martin Wendtner, Andrew W. Roberts, Matthew S. Davids, Johannes Bloehdorn, Talha Munir, Sebastian Bottcher, Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer Arzt, Su Young Kim, Maria Verdugo, Gary Gordon, Michael Hallek, William G. Wierda.
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial .
Journal of Clinical Oncology
2018 : Vol. 36, nr 9, s. 1973-1980
Autor korespondencyjny: Stephan Stilgenbauer.
p-ISSN: 0732-183X
AZ
ORG
AIF
IF: 28.245
Adres url:
Streszczenie w PubMed:
DOI:
7/11
Andrew D. Zelenetz, Jacqueline C. Barrientos, Jennifer R. Brown, Bertrand Coiffier, Julio Delgado, Miklós Egyed, Paolo Ghia, Árpad Illes, Wojciech Jurczak, Paula Marlton, Marco Montillo, Franck Morschhauser, Alexander S. Pristupa, Tadeusz Robak, Jeff P. Sharman, David Simpson, Lukas Smolej, Eugen Tausch, Adeboye H. Adewoye, Lyndah K. Dreiling, Yeonhee Kim, Stephan Stilgenbauer, Peter Hillmen.
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet. Oncology
2017 : Vol. 18, nr 3, s. 297-311, il., bibliogr. 22 poz., sum.
Autor korespondencyjny: Andrew D. Zelenetz.
p-ISSN: 1470-2045
AZ
ORG
AIF
IF: 36.418
Adres url:
Streszczenie w PubMed:
8/11
Farrukh T. Awan, Peter Hillmen, Andrzej Hellmann, Tadeusz Robak, Steven G. Hughes, Denise Trone, Megan Shannon, Ian W. Flinn, John C. Byrd, LUCID trial investigators.
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.
British Journal of Haematology
2014 : Vol. 164, nr 6, s. 466-477, il., bibliogr., sum.
p-ISSN: 0007-1048
AZ
ORG
AIF
IF: 4.711
Adres url:
Streszczenie w PubMed:
9/11
Peter Hillmen, Aleksander Skotnicki, Tadeusz Robak, Branimir Jaksic, Cynthia Sirard, Jiri Mayer.
Alemtuzumab (CAMPATH, MABCAMPATH) has superior progression free survival (PFS) vs Chlorambucil as front -line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
Blood
2006 : Vol. 108, nr 11 Part 1, s. 93a, abstr. 301
American Society of Hematology Forty-eight annual meeting, Orlando, Florida, December 9-12, 2006.
SZZ
SIF
10/11
Tadeusz Robak, Anna Dmoszynska, Raouf Fetni, Ying Wang, Malika Belkacz, Cynthia Sirard, Mark Goldberg, Aleksander Skotnicki, Jiri Mayer, Peter Hillmen.
Incidence of genomic aberrations and associated efficacy from a phase III study comparing alemtuzumab (CAMPATH, MABCAMPATH) vs chlorambucil as first line therapy for B-cell chronic lymphocytic leukemia (BCLL).
Blood
2006 : Vol. 108, nr 11 Part 1, s. 593a, abstr. 2093
American Society of Hematology Forty-eight annual meeting, Orlando, Florida, December 9-12, 2006.
SZZ
SIF
11/11
Peter Hillmen, Aleksander B. Skotnicki, Tadeusz Robak, Jiri Mayer, Branimir Jaksic, Vojo Vukovic, Steven Weitman.
Preliminary safety and efficacy report of a randomized trial of alemtuzumab vs chlorambucil as front-line therapy in 297 patients with progressive B-Cell chronic lymphocytic leukemia.
Blood
2004 : Vol. 104, nr 11 Part 1, s. 687a, abstr. 2505
American Society of Hematology Forty-six annual meeting, San Diego, California, December 4-7, 2004.
SZZ
SIF
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ